

Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Product name: 6,20% ERSTE Protect Multi US Pharma 19-20		
ISIN: AT0000A27FJ8	Issuer: Erste Group Bank AG	www.erstegroup.com/en/imprint
Call +43 (0)5 0100 – 10100 for more information	Regulator: Finanzmarktaufsicht (FMA)	Created: 5/21/2019

You are about to purchase a product that is not simple and may be difficult to understand.

What is this product?

Type

You invest into a debt obligation of the category Investment Product (Equity Linked Note).

Objectives

The aim is to obtain the highest possible yield by assuming the equity risk and bond risk. The product has a fixed interest rate and a fixed maturity. The redemption will depend on the performance of the underlyings. Interest is paid independent of the performance of the underlyings. There is no entitlement to other regular income (e.g. dividends of the underlyings).

At maturity, the product will be redeemed at the maximum redemption rate if the closing price of all underlyings remains above the barrier during the observation period. If the price of at least one underlying reaches or falls below the barrier during the observation period, the product will be redeemed at maturity according to the performance of the underlying with the worst performance; capped at the redemption rate. The performance of the underlying is equal to the result of dividing the closing price of the underlying on the valuation date by the strike price.

Underlyings:	Equity basket consisting of 3 shares.												
Issue Date:	4/29/2019												
Maturity Date:	4/29/2020												
Principal Amount:	1,000.00 EUR												
Interest Rate:	6.20%												
Payment Dates:	at maturity, 4/29/2020												
Valuation Date:	4/22/2020												
Observation Period:	4/26/2019 (excluding) – 4/22/2020 (including)												
Valuation Date:	4/22/2020												
Strike Price:	100.00% of the closing price on 4/26/2019												
Barrier:	60.00% of the strike price												
Underlying Table:	<table border="1"><thead><tr><th>Underlying Name:</th><th>Strike Price:</th><th>Barrier:</th></tr></thead><tbody><tr><td>BIOGEN INC.</td><td>230.53 USD</td><td>138.318 USD</td></tr><tr><td>ELI LILLY & CO.</td><td>119.87 USD</td><td>71.922 USD</td></tr><tr><td>ABBOTT LABORATORIES</td><td>78.56 USD</td><td>47.136 USD</td></tr></tbody></table>	Underlying Name:	Strike Price:	Barrier:	BIOGEN INC.	230.53 USD	138.318 USD	ELI LILLY & CO.	119.87 USD	71.922 USD	ABBOTT LABORATORIES	78.56 USD	47.136 USD
Underlying Name:	Strike Price:	Barrier:											
BIOGEN INC.	230.53 USD	138.318 USD											
ELI LILLY & CO.	119.87 USD	71.922 USD											
ABBOTT LABORATORIES	78.56 USD	47.136 USD											
Maximum Redemption Rate:	100.00%												


The issuer is entitled to terminate the product with immediate effect, if an extraordinary event occurs. Examples of extraordinary events include the delisting or loss of the underlying, changes in legislation, tax events and the discontinuation of the issuer's ability to carry out the necessary hedging transactions. In this case, the redemption amount may possibly be significantly below the purchase price. You also bear the risk that the product will be called in at a time unfavourable to you, and you may only be able to reinvest the redemption amount on less favourable terms.

Intended retail investor

This product is aimed at retail investors who can bear losses up to the total loss of the invested capital and prefer a short-term investment horizon. The retail investor has sufficient knowledge and / or experience with financial products. The retail investor has no clear (or significant) preference regarding capital growth and/or regular payments.

What are the risks and what could I get in return?

Risk Indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 6 out of 7, which is the second-highest risk class.

This rates the potential losses from future performance at a high level, and poor market conditions are very unlikely to impact our capacity to pay you.

Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

Performance scenarios

Market developments in the future cannot be accurately predicted. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower.

Investment of 10,000 EUR Scenarios		4/29/2020 (recommended holding period)
Stress scenario	What you might get back after cost	1,246.02 EUR
	Percentage return	-87.54%
Unfavorable scenario	What you might get back after cost	6,154.86 EUR
	Percentage return	-38.45%
Moderate scenario	What you might get back after cost	10,620.00 EUR
	Percentage return	6.20%
Favorable scenario	What you might get back after cost	10,620.00 EUR
	Percentage return	6.20%

This table shows the money you could get back over the recommended holding period assuming that you invest 10,000 EUR.

The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products. In general, the scenarios show the average return per year. If the recommended holding period is less than one year, the scenarios show the percentage return over the recommended holding period. Therefore, the comparability might be limited.

The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and are not an exact indicator. What you get will vary depending on how the market performs and how long you keep the product.

The stress scenario shows what you might get back in extreme market circumstances, and it does not take into account the situation where we are not able to pay you.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What happens if Erste Group Bank AG is unable to pay out?

This product is not covered by any deposit guarantee scheme. You are exposed to the risk that Erste Group Bank AG may not be able to fulfil its obligations arising from this product in the event of an insolvency (inability to pay, over-indebtedness) or from an official order ("bail-in regime"). A total loss of your invested capital is possible.

What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for one holding period. They include potential early exit penalties. The figures assume you invest 10,000 EUR. The figures are estimates and may change in the future.

Costs over time

Investment of 10,000 EUR Scenarios	4/29/2020 (recommended holding period)
Total costs	75.00 EUR
Impact on return (RIY)	0.80%

The person selling you or advising you about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.

Composition of costs

The table below shows:

- the impact of the different types of costs on the investment return you might get at the end of the recommended holding period;
- the meaning of the different cost categories.

This table shows the impact on return			
One-off costs	Entry costs	0.8025%	The impact of the costs already included in the price.
	Exit costs	0.00%	The impact of the costs of exiting your investment when it matures.
Ongoing costs	Other ongoing costs	0.00%	The impact of the costs that we take for managing your investments.

How long should I hold it and can I take money out early?

Recommended Holding Period: until 4/29/2020

The product is designed for staying invested until maturity date. The price is subject to fluctuations during the life of the product, which may result in losses. It is possible to sell the product during the respective trading hours at the given stock exchanges where this security is listed.

How can I complain?

In case of any complaint regarding the person advising on, or selling the product please contact your bank.

Any complaint regarding the product or the content of the document can be submitted to Erste Group Bank AG - Ombudsstelle, Am Belvedere 1, 1100 Wien. You may also send an e-mail to ombudsstelle@erstegroup.com or contact the following website: www.erstegroup.com/de/ueber-uns/ombudsmann-beschwerden.

Other relevant information

The binding legal basis for this security are only the information presented in the Final Terms and the Base Prospectus including its official supplements, which have been drawn in accordance with § 7 para. 4 of the Austrian Capital Market Act.

The Base Prospectus was published in accordance with the Directive of the European Parliament and of the Council 2003/71/EG, the European Commission Regulation (EC) no. 809/2004 and § 7 para. 4 of the Austrian Capital Market Act and approved by the Austrian Financial Market Authority (FMA).

To obtain full information on this security, in particular about the product characteristics and the risks associated with this investment, the Final Terms and, where appropriate, the base prospectus and its official appendices should be read. All documents can be requested from the Issuer Erste Group Bank AG, Am Belvedere 1, 1100 Wien and are also available on the website www.erstegroup.com.